FDA clears teclistamab plus daratumumab after first relapse, delivering striking PFS gains—plus practical tips to manage CRS, ICANS, and infections.
Shahrier Hossain, PharmD, BCOP
Advertisement
Articles by Shahrier Hossain, PharmD, BCOP
Belantamab mafodotin reenters clinical practice after FDA reapproval, signaling new potential for difficult-to-treat myeloma.
Advertisement
Latest Updated Articles
Tec-Dara: Match Made in Heaven or Double Trouble?June 16th 2026
Advertisement
Advertisement
Trending on Pharmacy Times
1
New CKD Outcome Set Tells Pharmacists What to Measure
2
State Pharmacy Boards Must Step Up Against Illegal Retatrutide
3
The PBM Reform Clock Is Running to 2028—Here's What Independent Pharmacies Should Do
4
GLP-1s and the HCM–Sleep Apnea–Obesity Connection
5